Cardiogene

Cardiogene was a pioneering cardiovascular gene therapy company founded in 1996 by prominent scientists Jeffrey Leiden, Elizabeth Nabel, and Gary Nabel. The company focused on developing novel genetic treatments for heart diseases, including restenosis, angiogenesis, and heart failure, utilizing adenoviral vectors to deliver therapeutic genes directly to the heart and blood vessels. Cardiogene's research was instrumental in the early development of vascular gene therapy, leading to its acquisition by Boston Scientific in 1998 for its promising technology and intellectual property. The company's work laid the foundation for subsequent advancements in the field of cardiac regenerative medicine and gene-based cardiovascular interventions.